ALK and non-small cell lung carcinoma: Patients with advanced non-small cell lung cancer and programmed cell death-ligand 1 expression ≥50% received cemiplimab monotherapy (n=283), and patients with no EGFR, ALK, or ROS1 genomic aberrations received cemiplimab plus chemotherapy (n=312).